Matrine induction of reactive oxygen species activates p38 leading to caspase-dependent cell apoptosis in non-small cell lung cancer cells

Tan,Caihong; Qian,Xiaoqiang; Jia,Rongdi; Wu,Min; Liang,Zhongqin

doi:10.3892/or.2013.2727

Matrine induction of reactive oxygen species activates p38 leading to caspase-dependent cell apoptosis in non-small cell lung cancer cells

Authors:
- Caihong Tan
- Xiaoqiang Qian
- Rongdi Jia
- Min Wu
- Zhongqin Liang
View Affiliations

Affiliations: College of Pharmacy, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Pharmacy, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China, Department of Neurosurgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
Published online on: September 9, 2013 https://doi.org/10.3892/or.2013.2727
Pages: 2529-2535

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung carcinoma (NSCLC) is one of the most refractory cancers in the clinic; it is insensitive to chemotherapy and is usually excised. However, screening natural compounds from herbs is also considered a possible method for its therapy. In the present study, we investigated whether matrine, a natural compound isolated from Sophora flavescens Ait. and exerting an inhibitory effect on lung cancer cells, also indicates inhibition on NSCLC cells and elucidated its molecular mechanism. Firstly, it is confirmed that matrine induces apoptosis of human NSCLC cells with anti-apoptotic factors inhibited and dependent on caspase activity. In addition, we found that matrine increases the phosphorylation of p38 but not its total protein, and inhibition of the p38 pathway with SB202190 partially prevents matrine-induced apoptosis. Furthermore, matrine generates reactive oxygen species (ROS) in a dose- and time-dependent manner, which is reversed by pretreatment with N-acetyl-L-cysteine (NAC). Additionally, inhibition of cell proliferation and increase of phosphorylation of p38 was also partially reversed by NAC. Collectively, matrine activates p38 pathway leading to a caspase-dependent apoptosis by inducing generation of ROS in NSCLC cells and may be a potential chemical for NSCLC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ioannidis G, Georgoulias V and Souglakos J: How close are we to customizing chemotherapy in early non-small cell lung cancer? Ther Adv Med Oncol. 3:185–205. 2011. View Article : Google Scholar : PubMed/NCBI
4	Sadowska AM, Nowé V, Janssens A, Boeykens E, De Backer WA and Germonpré PR: Customizing systemic therapy in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol. 3:207–218. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ancuceanu RV and Istudor V: Pharmacologically active natural compounds for lung cancer. Altern Med Rev. 9:402–419. 2004.PubMed/NCBI
6	Azzam HS, Goertz C, Fritts M and Jonas WB: Natural products and chronic hepatitis C virus. Liver Int. 27:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
7	Liu W, Tang JH and Wang YD: The research progress on Sophora flavescens Ait. Lishizhen Medicine and Materia Medica Research. 829–830. 2006.(In Chinese).
8	Zhang YL: Clinical study on matrine for the treatment of psoriasis. Hebei J Med Sci. 69:590–591. 1996.(In Chinese).
9	Liu M, Liu XY and Cheng JF: Advance in the pharmacological research on matrine. Zhongguo Zhong Yao Za Zhi. 28:801–804. 2003.(In Chinese).
10	Tan HR and Zhang BH: Experimental study of the anti-inflammatory effect of matrine. Zhong Xi Yi Jie He Za Zhi. 5:108–110. 691985.(In Chinese).
11	Chuang CY, Xiao JG and Chiou GC: Ocular anti-inflammatory actions of matrine. J Ocul Pharmacol. 3:129–134. 1987. View Article : Google Scholar : PubMed/NCBI
12	Liu JY, Hu JH, Zhu QG, Li FQ, Wang J and Sun HJ: Effect of matrine on the expression of substance P receptor and inflammatory cytokines production in human skin keratinocytes and fibroblasts. Int Immunopharmacol. 7:816–823. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ma L, Wen S, Zhan Y, He Y, Liu X and Jiang J: Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med. 74:245–251. 2008. View Article : Google Scholar : PubMed/NCBI
14	Ho JW, Ngan Hon PL and Chim WO: Effects of oxymatrine from Ku Shen on cancer cells. Anticancer Agents Med Chem. 9:823–826. 2009. View Article : Google Scholar : PubMed/NCBI
15	Jiang H, Hou C, Zhang S, et al: Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol. 559:98–108. 2007. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Zhang H, Yu P, et al: Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology. 59:191–200. 2009. View Article : Google Scholar : PubMed/NCBI
17	Li LQ, Li XL, Wang L, et al: Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem. 30:631–641. 2012. View Article : Google Scholar : PubMed/NCBI
18	Liu T, Song Y, Chen H, Pan S and Sun X: Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. Biol Pharm Bull. 33:1740–1745. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chen K, Hu ZQ, Wang T, Guo JL, Guo H and Ye ZQ: Matrine inhibits the proliferation of prostate cancer cells and the activity of androgen receptor. Zhonghua Nan Ke Xue. 14:719–722. 2008.(In Chinese).
20	Chen K, Hu Z, Wang T, Guo H and Ye Z: Inhibitory effect of matrine on the expression of PSA and AR in prostate cancer cell line LNCaP. J Huazhong Univ Sci Technolog Med Sci. 28:697–699. 2008. View Article : Google Scholar : PubMed/NCBI
21	Zhou XH, Wei X, Huang ZS, et al: Effects of matrine on proliferation and telomerase activity of colon cancer SW1116 cells. Zhong Yao Cai. 32:923–925. 2009.(In Chinese).
22	Yu P, Liu Q, Liu K, Yagasaki K, Wu E and Zhang G: Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-κB signaling. Cytotechnology. 59:219–229. 2009.PubMed/NCBI
23	Lu J, Luo Q, Cheng P, Liu X, Bai M and Tu M: The role of matrine and mitogen-activated protein kinase/extracellular signal-regulated kinase signal transduction in the inhibition of proliferation and migration of human umbilical vein endothelial cells induced by lung cancer cells. Zhongguo Fei Ai Za Zhi. 12:747–752. 2009.(In Chinese).
24	Zhu MY, Jiang ZH, Lu YW, Guo Y and Gan JJ: Matrine and anti-tumor drugs in inhibiting the growth of human lung cancer cell line. Zhong Xi Yi Jie He Xue Bao. 6:163–165. 2008.(In Chinese).
25	Saintigny P and Burger JA: Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 13:287–297. 2012.PubMed/NCBI
26	Aisner DL and Marshall CB: Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol. 138:332–346. 2012. View Article : Google Scholar : PubMed/NCBI
27	Young LC, Campling BG, Cole SP, Deeley RG and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 7:1798–1804. 2001.PubMed/NCBI
28	Bunn PJ and Kelly K: New combinations in the treatment of lung cancer: a time for optimism. Chest. 117(Suppl 1): S138–S143. 2000. View Article : Google Scholar : PubMed/NCBI
29	Gori B, Ricciardi S, del Signore E, Fulvi A and de Marinis F: Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets. 16(Suppl 2): S55–S60. 2012. View Article : Google Scholar : PubMed/NCBI
30	Bradham C and McClay DR: p38 MAPK in development and cancer. Cell Cycle. 5:824–828. 2006. View Article : Google Scholar : PubMed/NCBI
31	Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
32	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
33	Kumar P, Miller AI and Polverini PJ: p38 MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem. 279:43352–43360. 2004.
34	Park MT, Choi JA, Kim MJ, et al: Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J Biol Chem. 278:50624–50634. 2003. View Article : Google Scholar
35	Hancock JT, Desikan R and Neill SJ: Role of reactive oxygen species in cell signalling pathways. Biochem Soc Trans. 29:345–350. 2001. View Article : Google Scholar : PubMed/NCBI
36	Liou GY and Storz P: Reactive oxygen species in cancer. Free Radic Res. 44:479–496. 2010. View Article : Google Scholar : PubMed/NCBI
37	McCubrey JA, Lahair MM and Franklin RA: Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal. 8:1775–1789. 2006. View Article : Google Scholar : PubMed/NCBI
38	Dixit D, Sharma V, Ghosh S, Koul N, Mishra PK and Sen E: Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic Biol Med. 47:364–374. 2009. View Article : Google Scholar : PubMed/NCBI
39	Satriano J and Schlondorff D: Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J Clin Invest. 94:1629–1636. 1994.
40	Matalon S, Hardiman KM, Jain L, et al: Regulation of ion channel structure and function by reactive oxygen-nitrogen species. Am J Physiol Lung Cell Mol Physiol. 285:L1184–L1189. 2003. View Article : Google Scholar : PubMed/NCBI
41	Ushio-Fukai M and Nakamura Y: Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 266:37–52. 2008. View Article : Google Scholar : PubMed/NCBI